You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

~ Buy the AIRDUO RESPICLICK (fluticasone propionate; salmeterol xinafoate) Drug Profile, 2024 PDF Report in the Report Store ~

AIRDUO RESPICLICK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Airduo Respiclick, and when can generic versions of Airduo Respiclick launch?

Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are sixteen patents protecting this drug.

This drug has three hundred and fifty-one patent family members in thirty-seven countries.

The generic ingredient in AIRDUO RESPICLICK is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AIRDUO RESPICLICK?
  • What are the global sales for AIRDUO RESPICLICK?
  • What is Average Wholesale Price for AIRDUO RESPICLICK?
Drug patent expirations by year for AIRDUO RESPICLICK
Drug Prices for AIRDUO RESPICLICK

See drug prices for AIRDUO RESPICLICK

Pharmacology for AIRDUO RESPICLICK

US Patents and Regulatory Information for AIRDUO RESPICLICK

AIRDUO RESPICLICK is protected by sixteen US patents and two FDA Regulatory Exclusivities.

Patents protecting AIRDUO RESPICLICK

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing a medicament
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having a bore and shaft arrangement
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing a medicament
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting AIRDUO RESPICLICK

REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
Exclusivity Expiration: ⤷  Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-003 Jan 27, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-002 Jan 27, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-003 Jan 27, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AIRDUO RESPICLICK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-002 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-002 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for AIRDUO RESPICLICK

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva B.V. Airexar Spiromax salmeterol xinafoate, fluticasone propionate EMEA/H/C/004267
Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1
Withdrawn no no no 2016-08-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for AIRDUO RESPICLICK

See the table below for patents covering AIRDUO RESPICLICK around the world.

Country Patent Number Title Estimated Expiration
South Korea 101628934 ⤷  Sign Up
China 102655902 Airflow adaptor for a breath-actuated dry powder inhaler ⤷  Sign Up
South Korea 20130103825 DOSE COUNTERS FOR INHALERS, INHALERS AND SHAFTS THEREOF ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AIRDUO RESPICLICK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 132018000000341 Italy ⤷  Sign Up PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844 SPC/GB18/020 United Kingdom ⤷  Sign Up PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
1519731 132013902182575 Italy ⤷  Sign Up PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.